Adagene Inc. (ADAG)
ADAG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.46
-10.22% on the day
Market cap
$162.5M
Micro cap
Revenue · 2025
$7.7M
+7332.8% on 2024
Net income · 2025
-$17.6M
-229.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ADAG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | 2021 |
| SEC CIK | 0001818838 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | E9 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.7M |
| Net income | -$17.6M |
| Operating income | -$21.4M |
| Net margin | -229.6% |
| Operating margin | -279.5% |
| Revenue growth | +7332.8% |
| Cash | $74.5M |
| Total assets | $78.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 21.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-02 |
| Latest annual report | 20-F | 2026-04-01 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-09-25 |
Source: SEC EDGAR submissions feed, 191 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CNTN | Canton Strategic Holdings Inc. | $2.02 | -4.26% | $161.0M |
| DERM | Journey Medical Corporation | $5.68 | -3.89% | $160.3M |
| ORGO | Organogenesis Holdings Inc. | $1.21 | -1.63% | $155.7M |
| VRXA | Veraxa Biotech AG | $1.20 | +5.26% | $169.7M |
| MENS | Jyong Biotech Ltd. | $2.04 | -2.86% | $155.1M |
| WHWK | Whitehawk Therapeutics Inc. | $3.02 | -10.65% | $172.2M |
| YARW | Yarrow Bioscience Inc. | $18.60 | -6.16% | $173.1M |
| PEPG | PepGen Inc. | $2.50 | +0.40% | $173.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier